{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ACW.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ACW.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACW.AU\",,,,,undefined,":{"symbol":"ACW.AU","market":"AU","secType":"STK","nameCN":"ACTINOGEN MEDICAL LTD","latestPrice":0.03,"timestamp":1744870320000,"preClose":0.029,"halted":0,"volume":1153291,"delay":0,"nameEN":"ACTINOGEN MEDICAL LTD","floatShares":2334545946,"shares":3132147241,"eps":-0.003712,"marketStatus":"Not Yet Opened","change":0.001,"latestTime":"04-17 16:12:00 AEST","open":0.029,"high":0.03,"low":0.028,"amount":32510,"amplitude":0.068966,"askPrice":0.03,"askSize":211059,"bidPrice":0.027,"bidSize":1180538,"shortable":3,"etf":0,"ttmEps":-0.003712,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.029,"openAndCloseTimeList":[[1744848000000,1744869600000]],"volumeRatio":0.17629182499795956,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACW.AU\",,,,,undefined,":{"symbol":"ACW.AU","floatShares":2334545946,"roa":"-31.46%","roe":"-53.73%","lyrEps":-0.005999,"volumeRatio":0.17629182499795956,"shares":3132147241,"dividePrice":0,"high":0.03,"amplitude":0.068966,"preClose":0.029,"low":0.028,"week52Low":0.021,"pbRate":"3.92","psRate":"10.41","week52High":0.099,"institutionHeld":0,"latestPrice":0.03,"committee":0.696666,"eps":-0.003712,"divideRate":0,"volume":1153291,"delay":0,"ttmEps":-0.003712,"open":0.029,"prevYearClose":0.025,"prevWeekClose":0.03,"prevMonthClose":0.032,"prevQuarterClose":0.032,"fiveDayClose":0.028,"twentyDayClose":0.033,"sixtyDayClose":0.025},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ACW.AU\",params:#limit:6,delay:false,,,undefined,":[{"market":"AU","name":"Pharmaceutical Companies","bkCode":"BK7508","id":"package_au_concept_yyswg","changeRate":-0.007524}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACW.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522364586","title":"BRIEF-Actinogen Medical Acw Conducts Type C Meeting With FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2522364586","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522364586?lang=en_us&edition=fundamental","pubTime":"2025-03-27 09:17","pubTimestamp":1743038258,"startTime":"0","endTime":"0","summary":"BRIEF-Actinogen Medical Acw Conducts Type C Meeting With FDAMarch 27 (Reuters) - Actinogen Medical ACW.AX:ACW CONDUCTS TYPE C MEETING WITH FDA REGARDING DEPRESSIONFurther company coverage: ACW.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nFWN3Q91E8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","ACW.AU"],"gpt_icon":0},{"id":"2520535463","title":"Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2520535463","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520535463?lang=en_us&edition=fundamental","pubTime":"2025-03-17 08:14","pubTimestamp":1742170489,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse.So, the natural question for Actinogen Medical  shareholders is whether they should be concerned by its rate of cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.Since it has a market capitalisation of AU$94m, Actinogen Medical's AU$8.7m in cash burn equates to about 9.3% of its market value. That's a low proportion, so we figure the company would","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-were-not-too-001449807.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["ACW.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2517395908","title":"Xanamem: Alzheimer’s breakthrough set for 2025, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2517395908","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517395908?lang=en_us&edition=fundamental","pubTime":"2025-03-05 08:00","pubTimestamp":1741132800,"startTime":"0","endTime":"0","summary":"The search for an effective treatment for neurological conditions like Alzheimer’s disease remains one of the most urgent challenges in global healthcare. In 2025, Australian biotech company Actinogen Medical Ltd  is making significant strides in tackling this issue with its groundbreaking therapy, Xanamem.Actinogen has entered the new year with a major milestone: The World Health Organisation  granted Xanamem a medical, non-proprietary name – “emestedastat” – cementing its status as a novel treatment candidate.This key recognition not only validates the drug’s potential but also marks it as the first in a new class of medications designed to regulate brain cortisol levels; a critical factor in Alzheimer’s progression.“Based on positive outcomes in Phase 2 trials with the 10mg daily dose of Xanamem in both Alzheimer’s and major depression, we have strong confidence in the drug’s potential to drive meaningful progress in future trials.”The trial’s primary endpoint is the Clinical Dement","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/xanamem-alzheimers-breakthrough-set-for-2025-2026-2025-03-05/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["ACW.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2517084959","title":"Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2517084959","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517084959?lang=en_us&edition=fundamental","pubTime":"2025-03-05 07:35","pubTimestamp":1741131340,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-acw/actinogen-medical-shares/news/heres-why-were-not-too-worried-about-actinogen-medicals-asxa-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ACW.AU","BK7508","BK7067"],"gpt_icon":0}],"pageSize":4,"totalPage":6,"pageCount":1,"totalSize":24,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACW.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2020-10-19","symbol":"ACW.AU","defaultRemindTime":1603062000000,"type":"split","dateTimestamp":1603026000000,"forFactor":98,"toFactor":100,"ratio":0.98}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACW.AU\",market:\"AU\",,,undefined,":[]}}